德波提尼布在胆管癌中与MET放大:一个病例报告
Yen-Hao Chen1,2,3,4, Yu-Ting Huang3, Fang-Ying Kuo5
1Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 833, Taiwan.
OncoTargets and therapy
|November 4, 2024
概括
胆管癌治疗通过向治疗取得了进展. 在一个患者中发现的MET放大导致了tepotinib的成功治疗,显示了部分反应和持续的益处.
科学领域:
- 肝胆道恶性瘤 肝胆道恶性瘤
- 精确瘤学 精确瘤学
- 分子诊断学 分子诊断
背景情况:
- 胆管癌 (CCA) 是一种具有不良预后的侵袭性胆管癌.
- 对于不可手术的CCA,标准的第一线治疗包括gemcitabine加 cisplatin化疗.
- 对于在一线治疗中进展的患者而言,有效的选择有限.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.6K
